Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 Carriers
Tremonton
Archived
•
July 13, 2026
•
Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



